Levofloxacin-Induced Tendon Rupture: A Case Report and Review of the Literature

References

1. ↵
   Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23: 516–20.

   OpenUrlPubMedWeb of Science
2. ↵
   Physicians’ desk reference. Montvale, NJ: Medical Economics Co, 56th ed, 2002. Levaquin, p. 2537–43.
3. ↵
   Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747–50.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Weller S. Minerva. BMJ 2002; 324: 554.

   OpenUrlFREE Full Text
5. ↵
   Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl 3: 32–7; discussion 44–8.
6. ↵
   Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J 2000; 93: 488–91.

   OpenUrlPubMedWeb of Science
7. ↵
   McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 1996; 8: 496–8.

   OpenUrl
8. ↵
   Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease [letter]. N Z Med J 1983; 96: 590.

   OpenUrlPubMedWeb of Science
9. ↵
   McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis [letter]. Lancet 1988; 2: 900.

   OpenUrl
10. ↵
    Harrell RM. Fluoroquinolone-induced tendinopathy: what do we know? South Med J 1999; 92: 622–5.

    OpenUrlPubMedWeb of Science
11. ↵
    van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002; 324: 1306–7.

    OpenUrlFREE Full Text
12. ↵
    Gabutti L, Stoller R, Marti HP. Fluoroquinolones as etiology of tendinopathy. Ther Umsch 1998; 55: 558–61.

    OpenUrlPubMed
13. ↵
    Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Engl J Med 1994; 331: 748.

    OpenUrlCrossRefPubMed
14. ↵
    Jorgensen C, Anaya JM, Didry C, et al. Arthropathy with Achilles tendon involvement induced by pefloxacin. Apropos of a case. Rev Rhum Mal Osteoartic 1991; 58: 623–5.

    OpenUrlPubMed
15. ↵
    Williams RJ, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med 2000; 28: 364–9.

    OpenUrlAbstract/FREE Full Text
16. ↵
    Bernard-Beaubois K, Hecquet C, Hayem G, Rat P, Adolphe M. In vitro study of cytotoxicity of quinolones on rabbit tenocytes. Cell Biol Toxicol 1998; 14: 283–92.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Medwatch. Summary of safety-related drug labeling changes approved by FDA center for drug evaluation and research (CDER). Levaquin. Washington, DC: United States Food and Drug Administration; 2001 Dec. Available at: URL: http://www.fda.gov/medwatch/safety/2001/dec01.htm#levaqu
18. ↵
    Shakibaei M, de Souza P, van Sickle D, Stahlmann R. Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 2001; 75: 369–74.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Leppilahti J, Puranen J, Orava S. Incidence of Achilles tendon rupture. Acta Orthop Scand 1996; 67: 277–9.

    OpenUrlPubMedWeb of Science
20. ↵
    Maffulli N, Waterston SW, Squair J, Reaper J, Douglas AS. Changing incidence of Achilles tendon rupture in Scotland: a 15-year study. Clin J Sport Med 1999; 9: 157–60.

    OpenUrlPubMedWeb of Science